Cargando…

Dalcetrapib and anacetrapib increase apolipoprotein E-containing HDL in rabbits and humans

The large HDL particles generated by administration of cholesteryl ester transfer protein inhibitors (CETPi) remain poorly characterized, despite their potential importance in the routing of cholesterol to the liver for excretion, which is the last step of the reverse cholesterol transport. Thus, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brodeur, Mathieu R., Rhainds, David, Charpentier, Daniel, Boulé, Marie, Mihalache-Avram, Téodora, Mecteau, Mélanie, Brand, Geneviève, Pedneault-Gagnon, Valérie, Fortier, Annik, Niesor, Eric J., Rhéaume, Eric, Maugeais, Cyrille, Tardif, Jean-Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793321/ https://www.ncbi.nlm.nih.gov/pubmed/36410424 http://dx.doi.org/10.1016/j.jlr.2022.100316

Ejemplares similares

Dalcetrapib and anacetrapib differently impact HDL structure and function in rabbits and monkeys
por: Brodeur, Mathieu R., et al.
Publicado: (2017)

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes
por: Tardif, Jean-Claude, et al.
Publicado: (2016)

Inhibition of the 3CL Protease and SARS-CoV-2 Replication by Dalcetrapib
por: Niesor, Eric J, et al.
Publicado: (2021)

Optimisation of Reference Genes for Gene-Expression Analysis in a Rabbit Model of Left Ventricular Diastolic Dysfunction
por: Nachar, Walid, et al.
Publicado: (2014)

Cardiac inflammation and diastolic dysfunction in hypercholesterolemic rabbits
por: Nachar, Walid, et al.
Publicado: (2019)

Colchicine reduces lung injury in experimental acute respiratory distress syndrome
por: Dupuis, Jocelyn, et al.
Publicado: (2020)

Colchicine reduces atherosclerotic plaque vulnerability in rabbits
por: Roubille, François, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High‐Density Lipoprotein Cholesterol
por: Low‐Kam, Cécile, et al.
Publicado: (2018)

Validating Intravascular Imaging with Serial Optical Coherence Tomography and Confocal Fluorescence Microscopy
por: Tardif, Pier-Luc, et al.
Publicado: (2016)

Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?
por: Niesor, Eric J.
Publicado: (2015)

HDL as Bidirectional Lipid Vectors: Time for New Paradigms
por: Luna-Luna, María, et al.
Publicado: (2022)

Anacetrapib as a potential cardioprotective strategy
por: Di Bartolo, Belinda A, et al.
Publicado: (2017)

Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E
por: Millar, John S., et al.
Publicado: (2017)

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
por: Kühnast, Susan, et al.
Publicado: (2015)

Impact of ADCY9 Genotype on Response to Anacetrapib
por: Hopewell, Jemma C., et al.
Publicado: (2019)

Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease
por: Schwartz, Gregory G., et al.
Publicado: (2020)

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
por: Niesor, Eric J., et al.
Publicado: (2010)

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib
por: Goldberg, Alyse S, et al.
Publicado: (2012)

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial( )
por: Tardif, Jean Claude, et al.
Publicado: (2022)

Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity
por: Bobin-Dubigeon, Christine, et al.
Publicado: (2022)

Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
por: Filippatos, Theodosios D., et al.
Publicado: (2017)

Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
por: Metzinger, Mark P., et al.
Publicado: (2020)

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
por: Sammons, E, et al.
Publicado: (2021)

Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis
por: Santana, Monique F. M., et al.
Publicado: (2020)

In Vivo Near-Infrared Fluorescence Imaging of Atherosclerosis Using Local Delivery of Novel Targeted Molecular Probes
por: Bertrand, Marie-Jeanne, et al.
Publicado: (2019)

Apolipoprotein A-I modulates HDL particle size in the absence of apolipoprotein A-II
por: Melchior, John T., et al.
Publicado: (2021)

Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
por: Stein, Evan A., et al.
Publicado: (2010)

Erratum to: Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
Publicado: (2022)

How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations
por: Äijänen, Tarja, et al.
Publicado: (2014)

Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure()
por: Asselin, Caroline, et al.
Publicado: (2013)

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
por: Landray, M.J., et al.
Publicado: (2017)

Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
por: Contois, John H., et al.
Publicado: (2023)

Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib
por: Miyares, Marta A, et al.
Publicado: (2012)

Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381
Publicado: (2012)

Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease
por: Jensen, Majken K., et al.
Publicado: (2012)

CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
por: Thomas, Tiffany, et al.
Publicado: (2017)

Effect of fasting and feeding on apolipoprotein A-I kinetics in preβ(1)-HDL, α-HDL, and triglyceride-rich lipoproteins
por: Chétiveaux, Maud, et al.
Publicado: (2020)

Lipid-bound apolipoproteins in tyrosyl radical-oxidized HDL stabilize ABCA1 like lipid-free apolipoprotein A-I
por: Hossain, Mohammad A, et al.
Publicado: (2012)

Transport of Apolipoprotein B-Containing Lipoproteins through Endothelial Cells Is Associated with Apolipoprotein E-Carrying HDL-Like Particle Formation
por: Yang, Hong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_afja5tc0gjnohhserr0k9hpntb